InventisBio (SH:688382)2025-10-29 09:45Revenue and Profit - The company's revenue for the third quarter reached ¥11,729,619.53, representing a year-on-year increase of 173.86%[3] - The total profit for the period was -¥61,813,519.26, with a year-to-date total profit of -¥181,245,999.11[3] - The net profit attributable to shareholders was -¥61,813,519.26 for the quarter, and -¥181,385,152.31 year-to-date[3] - Total operating revenue for the first three quarters of 2025 reached ¥30,893,466.90, a significant increase from ¥19,156,299.24 in the same period of 2024, representing a growth of approximately 61.5%[20] - Net profit for the first three quarters of 2025 was reported at -¥181,385,152.31, an improvement compared to -¥305,306,509.72 in the same period of 2024, reflecting a reduction in losses of approximately 40.6%[21] Research and Development - Research and development expenses totaled ¥74,190,669.66, a decrease of 14.49% compared to the previous year[4] - The ratio of R&D expenses to revenue was 632.51%, down from 2,025.77% in the same period last year, a decrease of 1,393.26 percentage points[4] - Research and development expenses for the first three quarters of 2025 were ¥189,649,512.55, down from ¥295,676,116.12 in 2024, marking a decrease of approximately 35.8%[20] Assets and Liabilities - Total assets at the end of the period were ¥1,764,467,236.76, reflecting a decrease of 8.14% from the previous year[4] - Total current assets as of September 30, 2025, amount to ¥1,714,499,837.05, a decrease from ¥1,870,110,649.46 as of December 31, 2024[15] - Total assets as of September 30, 2025, are ¥1,764,467,236.76, down from ¥1,920,817,174.25[16] - The total liabilities decreased from ¥110,033,961.17 to ¥99,042,710.20, a reduction of about 10%[20] - The total equity attributable to shareholders decreased from ¥1,810,783,213.08 to ¥1,665,424,526.56, reflecting a decline of approximately 8%[20] Cash Flow - The company reported a net cash flow from operating activities of -¥160,056,383.93 year-to-date[3] - Cash flow from operating activities showed a net outflow of -¥160,056,383.93, which is an improvement from -¥289,602,708.75 in the previous year, indicating a 44.7% reduction in cash burn[23] - The net cash flow from investing activities was -$82.36 million, compared to -$181.56 million in the previous period, indicating an improvement[24] - The company’s cash and cash equivalents decreased by $243.78 million during the period, compared to a decrease of $476.30 million in the previous period[24] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 12,352[11] - The largest shareholder, InventisBio Hong Kong Limited, holds 110,329,937 shares, representing 19.08% of total shares[12] Other Financial Metrics - The basic earnings per share for the quarter was -¥0.11, and -¥0.31 year-to-date[3] - The company reported a basic and diluted earnings per share of -¥0.31 for the first three quarters of 2025, an improvement from -¥0.53 in the same period of 2024[21] - Other comprehensive income after tax showed a loss of -¥559,520.77, compared to -¥1,629,834.88 in the previous year, indicating a reduction in losses of approximately 65.7%[21] Corporate Governance - The board of directors announced the financial results on October 29, 2025, indicating ongoing corporate governance and transparency[26] - The company is set to implement new accounting standards starting in 2025, which may affect financial reporting[25]